Sign in

NCT05805020RecruitingPhase 3

Cellvizio to Evaluate Margins in Crohn's Ileal Disease

Is There a Concordance Between the Cellvizio With an Intravenous Injection of Fluorescein and the Pathology to Determine the Microscopic Inflammation at the Ileal Resection Margins in Crohn's Ileal Disease

Source: ClinicalTrials.gov · Last updated 28 May 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Crohn disease is an inflammatory bowel disease. A surgical procedure is required in about 80% of cases. Surgery doesn't cure from Crohn's disease but the type of surgery remains important as there are several intraoperative risk factors for recurrence. Among these factors the microscopic inflammation at the resection margins. This is a crucial point, if the resection is too large there is a risk of short bowel syndrome, if the resection is too short (microscopic inflammation at resection site), there is a higher risk of postoperative recurrence (75% vs 46% at 18 months). Surgeons have to do a limited resection (2cm from macroscopic crohn disease). However this macroscopic non inflammatory resection margin can be microscopically inflammatory (up to 80%). Thus it is useful to evaluate if there is a microscopic inflammation at the resection margin. Moreover there is an increase interest for the role of the mesentery for recurrence but its role remains unclear. It is of interest to clarify the border between the inflammatory and non-inflammatory mesentery. Cellvizio is a confocal laser endomicroscopy providing the possibility of obtaining in vivo high-magnification images of the gut epithelium. This allows real-time examination of the gastrointestinal mucosa at the cellular and subcellular level. Cellvizio has never been used during surgery for Crohn disease. The aim of this study is to evaluate the intraoperative use of Cellvizio (using the CelioFlex microsonde) with an intravenous injection of fluorescein to determine the best ileal resection margins in Crohn disease.

Status (registry)
Recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
41 (estimated)
First submitted
28 Mar 2023
Start date
3 Mar 2022
Primary completion date
Mar 2026
Lead sponsor
Centre Hospitalier Universitaire, Amiens
NCT number
NCT05805020
EU CT number
2024-517220-19-00
EudraCT number
2022-003499-18

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 41
  • From 3 Mar 2022 to the primary completion date, Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • patients who have a contra-indication for fluorescein injection or severe allergia to any drug

Other illness

  • patients who have an ileocolic resection for a surgical recurrence of the Crohn's disease.

Age

  • Patients\<18 years old,

Other

  • pregnancy or breastfeeding,
  • Patients operated in emergency for a peritonitis,

Who the study is looking for

  • Patients who need a ileocaecal resection for a Crohn disease whatever is the phenotype of the Crohn's disease

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Centre Hospitalier Universitaire Amiens Picardie
Coordinator of this site? Confirm its status
Amiens Cedex 1FranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.